A comparison of the effects of dopexamine and prostacyclin in systemic inflammatory response syndrome.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 10455827.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Forty critically ill patients fulfilling the definitions of systemic inflammatory response syndrome were enrolled in a double-blind cross-over interventional study assessing the effects of dopexamine and prostacyclin on splanchnic perfusion, cardiovascular function and oxygen flux. The cross-over design involved either dopexamine (1.25 micrograms.kg-1.min-1) or prostacyclin (0.5 ng.kg-1.min-1) being infused for 6 h followed by a 12-h washout period prior to an identical infusion sequence using the other agent. Preliminary analysis revealed a significant period effect, so data from the second infusion period were excluded from further analysis. Dopexamine caused a significant increase in heart rate (116 vs. 106 beat.min-1), and urine output (103 vs. 69 ml.h-1). Dopexamine produced a significant increase in oxygen delivery (infusion 548 ml O2.min-1.m-2; no infusion 492 ml O2.min-1.m-2) while prostacyclin caused a decrease (infusion 460 ml O2.min-1.m-2; no infusion 547 ml O2.min-1.m-2). The results indicate that dopexamine improves oxygen delivery and urine output more effectively than prostacyclin.
Medical subject headings
- Dopamine
- Epoprostenol
- Platelet Aggregation Inhibitors
- Systemic Inflammatory Response Syndrome
- Vasodilator Agents